How many drugs treat Chronic hepatitis C?

Drug Landscape tracks 10 marketed treatments for Chronic hepatitis C (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-hepatitis-c.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic hepatitis C — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic hepatitis C (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic hepatitis C, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mavyret	GLECAPREVIR	AbbVie	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
Zepatier	ELBASVIR	Merck & Co.	Hepatitis C Virus NS5A Inhibitor [EPC]		2016-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01
Viekira Pak (Copackaged)	DASABUVIR	AbbVie	Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor	Protein cereblon	2014-01-01
Victrelis	BOCEPREVIR	Merck & Co.	Hepatitis C Virus NS3/4A Protease Inhibitor	Chymase	2011-01-01
Pegasys	PEGINTERFERON ALFA-2A	Hoffman-La Roche		Interferon alpha/beta receptor	2002-01-01
Norvir	ritonavir	AbbVie	Cytochrome P450 3A Inhibitor [EPC]	Cytochrome P450 2C9	1996-01-01
Intron A	INTERFERON ALFA-2B	Merck & Co.	Interferon alpha		1986-01-01
Sovaldi	Sovaldi	Genuine Research Center, Egypt		Cereblon isoform 4, Genome polyprotein, NS5
Peginterferon	Peginterferon	Ziv Hospital	Interferon beta [EPC]	Interferon alpha/beta receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 4 drugs in Chronic hepatitis C
AbbVie · 3 drugs in Chronic hepatitis C
Genuine Research Center, Egypt · 2 drugs in Chronic hepatitis C
Bristol-Myers Squibb · 2 drugs in Chronic hepatitis C
Zealand University Hospital · 1 drug in Chronic hepatitis C
· 1 drug in Chronic hepatitis C
Ziv Hospital · 1 drug in Chronic hepatitis C
Charles University, Czech Republic · 1 drug in Chronic hepatitis C
Hoffman-La Roche · 1 drug in Chronic hepatitis C
Saint Michael's Medical Center · 1 drug in Chronic hepatitis C

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic hepatitis C:

Cite this brief

Drug Landscape (2026). Chronic hepatitis C — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-hepatitis-c. Accessed 2026-06-10.

Chronic hepatitis C full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing